A. Reif Et Al. , "Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.," 31st European Congress of Psychiatry (EPA) , Paris, France, 2023
Reif, A. Et Al. 2023. Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.. 31st European Congress of Psychiatry (EPA) , (Paris, France).
Reif, A., ANIL YAĞCIOĞLU, A. E., Luts, A., Messer, T., Nielsen, R., Buyze, J., ... İto, T.(2023). Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial. . 31st European Congress of Psychiatry (EPA), Paris, France
Reif, A Et Al. "Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.," 31st European Congress of Psychiatry (EPA), Paris, France, 2023
Reif, A Et Al. "Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.." 31st European Congress of Psychiatry (EPA) , Paris, France, 2023
Reif, A. Et Al. (2023) . "Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.." 31st European Congress of Psychiatry (EPA) , Paris, France.
@conferencepaper{conferencepaper, author={A Reif Et Al. }, title={Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomized, phase IIIb clinical trial.}, congress name={31st European Congress of Psychiatry (EPA)}, city={Paris}, country={France}, year={2023}}